An Open Label, Phase 2a Clinical Trial for the Evaluation of Safety and Efficacy of RZL-012 for the Treatment of Women With Lipedema Involving Substantial Fat Above the Knee or of Women and Men With Nodular Dercum's Disease
Phase of Trial: Phase II
Latest Information Update: 15 May 2019
Price : $35 *
At a glance
- Drugs RZL-012 (Primary)
- Indications Adiposis dolorosa; Lipoedema
- Focus Adverse reactions
- Sponsors Raziel Therapeutics
- 13 May 2019 Status changed from recruiting to completed.
- 21 Apr 2019 Planned End Date changed from 1 Sep 2018 to 30 May 2019.
- 21 Apr 2019 Planned primary completion date changed from 1 Aug 2018 to 30 May 2019.